英國首相伯納姆：（在被問及增稅問題時表示）我們將在預算中做出稅收決策。

Sinopharm CNBG’s Shanghai Institute of Biological Products has received a batch release certificate for its inactivated split‑virus influenza vaccine, marking the product’s market launch for the 2026–27 season. The vaccine was developed to the WHO‑recommended 2026–27 Northern Hemisphere influenza strains.

Huaxi Securities deputy GM and head of research Wei Tao said on July 22 the recent pullback is a healthy technical repair after rapid gains. Since April 2026 the tech complex led strong rallies and some sectors saw sharp valuation expansion, creating an objective need for re‑rating and position transfer. Recent adjustments have digested prior profit taking and released some short‑term irrational selling. Rebound conditions are gradually maturing: broad indices’ valuations have fallen to relative year lows, improving margins of safety; leverage risk has been reduced as margin‑financing balances have declined materially; mainstream broad ETFs have attracted cash at low levels, signalling greater long‑term fund acceptance of current prices. Falling crowding and a more balanced trading structure have opened technical space for a rebound.